Neurodegenerative disorders—Searching for targets and new ways of diseases treatment

Abstract

Research and development of efficient therapeutic strategies for the treatment of neurodegenerative diseases is one of the most risky and challenging problems of modern neuromedicine. At the same time, the social and economic importance of the solution, at least in part, of these problems outweighs any possible risks and development costs. Such common neurodegenerative diseases as Alzheimer's or Parkinson's diseases were described more than 100 years ago, but they are still uncurable. Notwithstanding the substantial progress in our understanding of the pathogenesis of these diseases, the triggers and detailed mechanisms of neurodegeneration remain unclear. 1,2 It hampers focused search of novel efficient neuroprotectors and therapeutic strategies that could prevent the development of such neurodegenerative diseases.

Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

“…The presently available conventional therapeutic options for disease management are only limited to damage control due to challenges in identifiable-tractable treatment targets, controlled-cum-targeted drug delivery as well as postinjury tissue repair. 41 From this standpoint, the development of multitarget drug candidates seems highly promising, which can target different risk factors involved in the pathogenesis of different NDDs. Platelet hyperactivation seems to be an important event associated with the majority of the NDDs, for which antiplatelet drugs could be the therapeutic options (Figure 2).…”

“…Currently, there are no licensed treatments available for NDDs due to their multifactorial etiology in addition to their late‐onset of symptom appearance. The presently available conventional therapeutic options for disease management are only limited to damage control due to challenges in identifiable‐tractable treatment targets, controlled‐cum‐targeted drug delivery as well as postinjury tissue repair 41 . From this standpoint, the development of multitarget drug candidates seems highly promising, which can target different risk factors involved in the pathogenesis of different NDDs.…”

The Neuroprotective Potential of Endophytic Fungi and Proposed Molecular Mechanism: A Current Update

“…Neurodegenerative diseases (ND) include debilitating conditions that pose a serious threat to the human health leading to progressive degeneration of nerve cells. e brain disorders like Alzheimer's disease (AD), ataxia, Parkinson's disease (PD), multiple system atrophy, autism, are significantly linked to insufficient production of neurotransmitters, abnormal ubiquitination, aggregation of abnormal proteins followed by inflammation, and oxidative stress in the central nervous system (CNS) [1][2][3]. Although, there has been progression in our understanding about ND, the potential triggers of such disorders and their molecular mechanisms are still uncertain [1,3].…”

“…e brain disorders like Alzheimer's disease (AD), ataxia, Parkinson's disease (PD), multiple system atrophy, autism, are significantly linked to insufficient production of neurotransmitters, abnormal ubiquitination, aggregation of abnormal proteins followed by inflammation, and oxidative stress in the central nervous system (CNS) [1][2][3]. Although, there has been progression in our understanding about ND, the potential triggers of such disorders and their molecular mechanisms are still uncertain [1,3]. Currently, no reliable cure is being available for the treatment of ND due to limited regeneration ability of CNS [4,5].…”

Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China

“…It can be argued that pharmacological research and development (R&D) in the field of AD treatment is slow compared to other disease areas and is in a state of constant wandering and investigation. Research progress on potentially effective neuroprotectors and therapeutic strategies that prevent the development of AD is stalled because of a lack of adequate understanding of the intricate mechanisms of neurodegeneration ( 7 ). Apart from the above reasons, imperfect preclinical models and lack of validated diagnosis contribute to the high failure rate in the development of AD ( 8 ).…”